Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 73,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'catslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 73,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [[maximum depth reached]]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/ranbaxy-drugs-fine-say-who-and-uk-regulator-rema-nagarajan-21718/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/ranbaxy-drugs-fine-say-who-and-uk-regulator-rema-nagarajan-21718/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'catslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 73
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 74,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'artileslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 74,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [[maximum depth reached]]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/ranbaxy-drugs-fine-say-who-and-uk-regulator-rema-nagarajan-21718/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/ranbaxy-drugs-fine-say-who-and-uk-regulator-rema-nagarajan-21718/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'artileslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 74
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Warning (512): Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853 [CORE/src/Http/ResponseEmitter.php, line 48]
Code Context
            if (Configure::read('debug')) {

                trigger_error($message, E_USER_WARNING);

            } else {
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67fa0d1f1011a-trace').style.display = (document.getElementById('cakeErr67fa0d1f1011a-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67fa0d1f1011a-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67fa0d1f1011a-code').style.display = (document.getElementById('cakeErr67fa0d1f1011a-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67fa0d1f1011a-context').style.display = (document.getElementById('cakeErr67fa0d1f1011a-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67fa0d1f1011a-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67fa0d1f1011a-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 21571,
		&#039;title&#039; =&gt; &#039;Ranbaxy drugs fine, say WHO and UK regulator -Rema Nagarajan&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Times of India
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;NEW DELHI: &lt;/em&gt;In yet another twist to the Ranbaxy scandal, the drug regulatory authority of the UK government has issued a statement clarifying that they have found no evidence of any Ranbaxy product in the UK market having been &amp;quot;of unacceptable quality&amp;quot;. Last month, WHO had issued a similar statement. It had said that there was no evidence of any of the Ranbaxy products being of unacceptable quality.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Medicines and Healthcare products Regulatory Authority (MHRA) of UK explained that on hearing that Ranbaxy had pleaded guilty to felony charges related to drugs made at two facilities in India it had performed a number of inspections of Ranbaxy sites along with other international regulators including the USFDA and the WHO.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
While some failures to comply with good manufacturing practice (GMP) were reported, the inspections did not find any Ranbaxy products in the UK market being either of unacceptable quality or putting UK patients at risk. The statement clarified: &amp;quot;As part of their investigations the MHRA has tested samples of Ranbaxy products taken from the UK market. All samples met the correct quality specifications.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
MHRA explained how it has been inspecting Ranbaxy sites since 1995 for GMP compliance and elaborated how following USFDA concerns in 2008, MHRA was part of multinational inspection teams which found that while the company complied in general with European Union (EU) GMP they needed to demonstrate continued commitment to improving standards of compliance. Continuing inspections by international teams showed that &amp;quot;the company had made significant progress&amp;quot;.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
According to the MHRA, India is the biggest supplier of Active Pharmaceutical Ingredients (APIs) to the EU and in the last financial year, of the 116 overseas inspections conducted by MHRA, 47 were performed in India and 52 were performed in the US. &amp;quot;There is not a noticeable difference in the number of significant findings identified at UK sites versus those overseas,&amp;quot; added the MHRA. In the UK 23% of UK Marketing Authorisations name an Indian manufacturer and 38% name an Indian API source.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
WHO in its statement explained that it has a number of finished pharmaceutical products (FPPs), mostly HIV/AIDS drugs, manufactured by Ranbaxy on its pre-qualified list and added that a number of generic medicines prequalified by the WHO Pre-Qualification Programme (WHO-PQP), including those of Ranbaxy, have also been approved by stringent regulatory authorities (SRAs). SRAs are those national medicines regulatory authorities which are members, observers or associates of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The WHO-PQP statement explained: &amp;quot;In the USA, the term &amp;quot;adulterated&amp;quot; has a specific legal meaning. If a company is not complying with Current Good Manufacturing Practice Regulations (cGMP), any medicines that it manufactures are considered to be &amp;quot;adulterated&amp;quot; under the law. In other words, its medicines are not manufactured under conditions that comply with cGMP. It does not mean that the medicine is necessarily substandard.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Medicines Control Council (MCC) of South Africa too has assured that Ranbaxy drugs were safe and effective. MCC was part of several inspections conducted of Ranbaxy&#039;s manufacturing sites. However, the WHO as well as the MCC said that, in 2004, there were problems with Ranbaxy such as with missing data, changes to dates in documentation, and comparative data not being credible which led to many drugs being recalled from the market. But they state that it was fixed over several inspections conducted later. MCC also stated that after FDA banned products from the Paonta Sahib plant of Ranbaxy in 2006, random tests of Ranbaxy drugs on the South African market found no critical deficiencies.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
According to the WHO, after USFDA issued a warning to Ranbaxy in 2008, WHO-PQP organized several inspection since the Paonta Sahib site also manufactured drugs on WHO&#039;s prequalified list. One of these inspections was conducted in November 2008 by a team of 6 inspectors - 3 from WHOPQP, one from the Therapeutic Goods Administration (TGA) of Australia, one from Health Canada and one from MHRA, UK. Some non-compliances were observed and Ranbaxy thereafter submitted documentation describing corrective and preventive actions, which were assessed by the inspection team and found acceptable. &amp;quot;There was no evidence to warrant any further action by WHO-PQP, or indeed by those SRAs who participated in this inspection,&amp;quot; said WHO adding that WHO-PQP has continued to monitor Ranbaxy and all other manufacturers on the WHO list.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
WHO concluded by giving a list of all the inspections it has conducted along with regulatory authorities from various countries- Swtizerland, France, Hungary, Australia, Kenya, Tanzania South Africa and the UK --since 2000 in Ranbaxy manufacturing sites in Dewas, Mohali and Paonta Sahib.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;nbsp;
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Times of India, 28 June, 2013, http://timesofindia.indiatimes.com/business/india-business/Ranbaxy-drugs-fine-say-WHO-and-UK-regulator/articleshow/20806204.cms&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;ranbaxy-drugs-fine-say-who-and-uk-regulator-rema-nagarajan-21718&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 21718,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 21571,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Ranbaxy drugs fine, say WHO and UK regulator -Rema Nagarajan&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;medicines,Ranbaxy,Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Times of India



NEW DELHI: In yet another twist to the Ranbaxy scandal, the drug regulatory authority of the UK government has issued a statement clarifying that they have found no evidence of any Ranbaxy product in the UK market...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Times of India&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;NEW DELHI: &lt;/em&gt;In yet another twist to the Ranbaxy scandal, the drug regulatory authority of the UK government has issued a statement clarifying that they have found no evidence of any Ranbaxy product in the UK market having been &amp;quot;of unacceptable quality&amp;quot;. Last month, WHO had issued a similar statement. It had said that there was no evidence of any of the Ranbaxy products being of unacceptable quality.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Medicines and Healthcare products Regulatory Authority (MHRA) of UK explained that on hearing that Ranbaxy had pleaded guilty to felony charges related to drugs made at two facilities in India it had performed a number of inspections of Ranbaxy sites along with other international regulators including the USFDA and the WHO.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;While some failures to comply with good manufacturing practice (GMP) were reported, the inspections did not find any Ranbaxy products in the UK market being either of unacceptable quality or putting UK patients at risk. The statement clarified: &amp;quot;As part of their investigations the MHRA has tested samples of Ranbaxy products taken from the UK market. All samples met the correct quality specifications.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;MHRA explained how it has been inspecting Ranbaxy sites since 1995 for GMP compliance and elaborated how following USFDA concerns in 2008, MHRA was part of multinational inspection teams which found that while the company complied in general with European Union (EU) GMP they needed to demonstrate continued commitment to improving standards of compliance. Continuing inspections by international teams showed that &amp;quot;the company had made significant progress&amp;quot;.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;According to the MHRA, India is the biggest supplier of Active Pharmaceutical Ingredients (APIs) to the EU and in the last financial year, of the 116 overseas inspections conducted by MHRA, 47 were performed in India and 52 were performed in the US. &amp;quot;There is not a noticeable difference in the number of significant findings identified at UK sites versus those overseas,&amp;quot; added the MHRA. In the UK 23% of UK Marketing Authorisations name an Indian manufacturer and 38% name an Indian API source.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;WHO in its statement explained that it has a number of finished pharmaceutical products (FPPs), mostly HIV/AIDS drugs, manufactured by Ranbaxy on its pre-qualified list and added that a number of generic medicines prequalified by the WHO Pre-Qualification Programme (WHO-PQP), including those of Ranbaxy, have also been approved by stringent regulatory authorities (SRAs). SRAs are those national medicines regulatory authorities which are members, observers or associates of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The WHO-PQP statement explained: &amp;quot;In the USA, the term &amp;quot;adulterated&amp;quot; has a specific legal meaning. If a company is not complying with Current Good Manufacturing Practice Regulations (cGMP), any medicines that it manufactures are considered to be &amp;quot;adulterated&amp;quot; under the law. In other words, its medicines are not manufactured under conditions that comply with cGMP. It does not mean that the medicine is necessarily substandard.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Medicines Control Council (MCC) of South Africa too has assured that Ranbaxy drugs were safe and effective. MCC was part of several inspections conducted of Ranbaxy&#039;s manufacturing sites. However, the WHO as well as the MCC said that, in 2004, there were problems with Ranbaxy such as with missing data, changes to dates in documentation, and comparative data not being credible which led to many drugs being recalled from the market. But they state that it was fixed over several inspections conducted later. MCC also stated that after FDA banned products from the Paonta Sahib plant of Ranbaxy in 2006, random tests of Ranbaxy drugs on the South African market found no critical deficiencies.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;According to the WHO, after USFDA issued a warning to Ranbaxy in 2008, WHO-PQP organized several inspection since the Paonta Sahib site also manufactured drugs on WHO&#039;s prequalified list. One of these inspections was conducted in November 2008 by a team of 6 inspectors - 3 from WHOPQP, one from the Therapeutic Goods Administration (TGA) of Australia, one from Health Canada and one from MHRA, UK. Some non-compliances were observed and Ranbaxy thereafter submitted documentation describing corrective and preventive actions, which were assessed by the inspection team and found acceptable. &amp;quot;There was no evidence to warrant any further action by WHO-PQP, or indeed by those SRAs who participated in this inspection,&amp;quot; said WHO adding that WHO-PQP has continued to monitor Ranbaxy and all other manufacturers on the WHO list.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;WHO concluded by giving a list of all the inspections it has conducted along with regulatory authorities from various countries- Swtizerland, France, Hungary, Australia, Kenya, Tanzania South Africa and the UK --since 2000 in Ranbaxy manufacturing sites in Dewas, Mohali and Paonta Sahib.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;nbsp;&lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 21571,
	&#039;title&#039; =&gt; &#039;Ranbaxy drugs fine, say WHO and UK regulator -Rema Nagarajan&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Times of India
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;NEW DELHI: &lt;/em&gt;In yet another twist to the Ranbaxy scandal, the drug regulatory authority of the UK government has issued a statement clarifying that they have found no evidence of any Ranbaxy product in the UK market having been &amp;quot;of unacceptable quality&amp;quot;. Last month, WHO had issued a similar statement. It had said that there was no evidence of any of the Ranbaxy products being of unacceptable quality.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Medicines and Healthcare products Regulatory Authority (MHRA) of UK explained that on hearing that Ranbaxy had pleaded guilty to felony charges related to drugs made at two facilities in India it had performed a number of inspections of Ranbaxy sites along with other international regulators including the USFDA and the WHO.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
While some failures to comply with good manufacturing practice (GMP) were reported, the inspections did not find any Ranbaxy products in the UK market being either of unacceptable quality or putting UK patients at risk. The statement clarified: &amp;quot;As part of their investigations the MHRA has tested samples of Ranbaxy products taken from the UK market. All samples met the correct quality specifications.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
MHRA explained how it has been inspecting Ranbaxy sites since 1995 for GMP compliance and elaborated how following USFDA concerns in 2008, MHRA was part of multinational inspection teams which found that while the company complied in general with European Union (EU) GMP they needed to demonstrate continued commitment to improving standards of compliance. Continuing inspections by international teams showed that &amp;quot;the company had made significant progress&amp;quot;.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
According to the MHRA, India is the biggest supplier of Active Pharmaceutical Ingredients (APIs) to the EU and in the last financial year, of the 116 overseas inspections conducted by MHRA, 47 were performed in India and 52 were performed in the US. &amp;quot;There is not a noticeable difference in the number of significant findings identified at UK sites versus those overseas,&amp;quot; added the MHRA. In the UK 23% of UK Marketing Authorisations name an Indian manufacturer and 38% name an Indian API source.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
WHO in its statement explained that it has a number of finished pharmaceutical products (FPPs), mostly HIV/AIDS drugs, manufactured by Ranbaxy on its pre-qualified list and added that a number of generic medicines prequalified by the WHO Pre-Qualification Programme (WHO-PQP), including those of Ranbaxy, have also been approved by stringent regulatory authorities (SRAs). SRAs are those national medicines regulatory authorities which are members, observers or associates of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The WHO-PQP statement explained: &amp;quot;In the USA, the term &amp;quot;adulterated&amp;quot; has a specific legal meaning. If a company is not complying with Current Good Manufacturing Practice Regulations (cGMP), any medicines that it manufactures are considered to be &amp;quot;adulterated&amp;quot; under the law. In other words, its medicines are not manufactured under conditions that comply with cGMP. It does not mean that the medicine is necessarily substandard.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Medicines Control Council (MCC) of South Africa too has assured that Ranbaxy drugs were safe and effective. MCC was part of several inspections conducted of Ranbaxy&#039;s manufacturing sites. However, the WHO as well as the MCC said that, in 2004, there were problems with Ranbaxy such as with missing data, changes to dates in documentation, and comparative data not being credible which led to many drugs being recalled from the market. But they state that it was fixed over several inspections conducted later. MCC also stated that after FDA banned products from the Paonta Sahib plant of Ranbaxy in 2006, random tests of Ranbaxy drugs on the South African market found no critical deficiencies.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
According to the WHO, after USFDA issued a warning to Ranbaxy in 2008, WHO-PQP organized several inspection since the Paonta Sahib site also manufactured drugs on WHO&#039;s prequalified list. One of these inspections was conducted in November 2008 by a team of 6 inspectors - 3 from WHOPQP, one from the Therapeutic Goods Administration (TGA) of Australia, one from Health Canada and one from MHRA, UK. Some non-compliances were observed and Ranbaxy thereafter submitted documentation describing corrective and preventive actions, which were assessed by the inspection team and found acceptable. &amp;quot;There was no evidence to warrant any further action by WHO-PQP, or indeed by those SRAs who participated in this inspection,&amp;quot; said WHO adding that WHO-PQP has continued to monitor Ranbaxy and all other manufacturers on the WHO list.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
WHO concluded by giving a list of all the inspections it has conducted along with regulatory authorities from various countries- Swtizerland, France, Hungary, Australia, Kenya, Tanzania South Africa and the UK --since 2000 in Ranbaxy manufacturing sites in Dewas, Mohali and Paonta Sahib.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;nbsp;
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Times of India, 28 June, 2013, http://timesofindia.indiatimes.com/business/india-business/Ranbaxy-drugs-fine-say-WHO-and-UK-regulator/articleshow/20806204.cms&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;ranbaxy-drugs-fine-say-who-and-uk-regulator-rema-nagarajan-21718&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 21718,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 21571
$metaTitle = &#039;LATEST NEWS UPDATES | Ranbaxy drugs fine, say WHO and UK regulator -Rema Nagarajan&#039;
$metaKeywords = &#039;medicines,Ranbaxy,Health&#039;
$metaDesc = &#039;
-The Times of India



NEW DELHI: In yet another twist to the Ranbaxy scandal, the drug regulatory authority of the UK government has issued a statement clarifying that they have found no evidence of any Ranbaxy product in the UK market...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Times of India&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;NEW DELHI: &lt;/em&gt;In yet another twist to the Ranbaxy scandal, the drug regulatory authority of the UK government has issued a statement clarifying that they have found no evidence of any Ranbaxy product in the UK market having been &amp;quot;of unacceptable quality&amp;quot;. Last month, WHO had issued a similar statement. It had said that there was no evidence of any of the Ranbaxy products being of unacceptable quality.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Medicines and Healthcare products Regulatory Authority (MHRA) of UK explained that on hearing that Ranbaxy had pleaded guilty to felony charges related to drugs made at two facilities in India it had performed a number of inspections of Ranbaxy sites along with other international regulators including the USFDA and the WHO.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;While some failures to comply with good manufacturing practice (GMP) were reported, the inspections did not find any Ranbaxy products in the UK market being either of unacceptable quality or putting UK patients at risk. The statement clarified: &amp;quot;As part of their investigations the MHRA has tested samples of Ranbaxy products taken from the UK market. All samples met the correct quality specifications.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;MHRA explained how it has been inspecting Ranbaxy sites since 1995 for GMP compliance and elaborated how following USFDA concerns in 2008, MHRA was part of multinational inspection teams which found that while the company complied in general with European Union (EU) GMP they needed to demonstrate continued commitment to improving standards of compliance. Continuing inspections by international teams showed that &amp;quot;the company had made significant progress&amp;quot;.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;According to the MHRA, India is the biggest supplier of Active Pharmaceutical Ingredients (APIs) to the EU and in the last financial year, of the 116 overseas inspections conducted by MHRA, 47 were performed in India and 52 were performed in the US. &amp;quot;There is not a noticeable difference in the number of significant findings identified at UK sites versus those overseas,&amp;quot; added the MHRA. In the UK 23% of UK Marketing Authorisations name an Indian manufacturer and 38% name an Indian API source.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;WHO in its statement explained that it has a number of finished pharmaceutical products (FPPs), mostly HIV/AIDS drugs, manufactured by Ranbaxy on its pre-qualified list and added that a number of generic medicines prequalified by the WHO Pre-Qualification Programme (WHO-PQP), including those of Ranbaxy, have also been approved by stringent regulatory authorities (SRAs). SRAs are those national medicines regulatory authorities which are members, observers or associates of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The WHO-PQP statement explained: &amp;quot;In the USA, the term &amp;quot;adulterated&amp;quot; has a specific legal meaning. If a company is not complying with Current Good Manufacturing Practice Regulations (cGMP), any medicines that it manufactures are considered to be &amp;quot;adulterated&amp;quot; under the law. In other words, its medicines are not manufactured under conditions that comply with cGMP. It does not mean that the medicine is necessarily substandard.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Medicines Control Council (MCC) of South Africa too has assured that Ranbaxy drugs were safe and effective. MCC was part of several inspections conducted of Ranbaxy&#039;s manufacturing sites. However, the WHO as well as the MCC said that, in 2004, there were problems with Ranbaxy such as with missing data, changes to dates in documentation, and comparative data not being credible which led to many drugs being recalled from the market. But they state that it was fixed over several inspections conducted later. MCC also stated that after FDA banned products from the Paonta Sahib plant of Ranbaxy in 2006, random tests of Ranbaxy drugs on the South African market found no critical deficiencies.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;According to the WHO, after USFDA issued a warning to Ranbaxy in 2008, WHO-PQP organized several inspection since the Paonta Sahib site also manufactured drugs on WHO&#039;s prequalified list. One of these inspections was conducted in November 2008 by a team of 6 inspectors - 3 from WHOPQP, one from the Therapeutic Goods Administration (TGA) of Australia, one from Health Canada and one from MHRA, UK. Some non-compliances were observed and Ranbaxy thereafter submitted documentation describing corrective and preventive actions, which were assessed by the inspection team and found acceptable. &amp;quot;There was no evidence to warrant any further action by WHO-PQP, or indeed by those SRAs who participated in this inspection,&amp;quot; said WHO adding that WHO-PQP has continued to monitor Ranbaxy and all other manufacturers on the WHO list.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;WHO concluded by giving a list of all the inspections it has conducted along with regulatory authorities from various countries- Swtizerland, France, Hungary, Australia, Kenya, Tanzania South Africa and the UK --since 2000 in Ranbaxy manufacturing sites in Dewas, Mohali and Paonta Sahib.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;nbsp;&lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/ranbaxy-drugs-fine-say-who-and-uk-regulator-rema-nagarajan-21718.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Ranbaxy drugs fine, say WHO and UK regulator -Rema Nagarajan | Im4change.org</title>
    <meta name="description" content="
-The Times of India



NEW DELHI: In yet another twist to the Ranbaxy scandal, the drug regulatory authority of the UK government has issued a statement clarifying that they have found no evidence of any Ranbaxy product in the UK market..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Ranbaxy drugs fine, say WHO and UK regulator -Rema Nagarajan</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Times of India</div><p align="justify"><br /><em>NEW DELHI: </em>In yet another twist to the Ranbaxy scandal, the drug regulatory authority of the UK government has issued a statement clarifying that they have found no evidence of any Ranbaxy product in the UK market having been &quot;of unacceptable quality&quot;. Last month, WHO had issued a similar statement. It had said that there was no evidence of any of the Ranbaxy products being of unacceptable quality.</p><p align="justify">The Medicines and Healthcare products Regulatory Authority (MHRA) of UK explained that on hearing that Ranbaxy had pleaded guilty to felony charges related to drugs made at two facilities in India it had performed a number of inspections of Ranbaxy sites along with other international regulators including the USFDA and the WHO.</p><p align="justify">While some failures to comply with good manufacturing practice (GMP) were reported, the inspections did not find any Ranbaxy products in the UK market being either of unacceptable quality or putting UK patients at risk. The statement clarified: &quot;As part of their investigations the MHRA has tested samples of Ranbaxy products taken from the UK market. All samples met the correct quality specifications.&quot;</p><p align="justify">MHRA explained how it has been inspecting Ranbaxy sites since 1995 for GMP compliance and elaborated how following USFDA concerns in 2008, MHRA was part of multinational inspection teams which found that while the company complied in general with European Union (EU) GMP they needed to demonstrate continued commitment to improving standards of compliance. Continuing inspections by international teams showed that &quot;the company had made significant progress&quot;.</p><p align="justify">According to the MHRA, India is the biggest supplier of Active Pharmaceutical Ingredients (APIs) to the EU and in the last financial year, of the 116 overseas inspections conducted by MHRA, 47 were performed in India and 52 were performed in the US. &quot;There is not a noticeable difference in the number of significant findings identified at UK sites versus those overseas,&quot; added the MHRA. In the UK 23% of UK Marketing Authorisations name an Indian manufacturer and 38% name an Indian API source.</p><p align="justify">WHO in its statement explained that it has a number of finished pharmaceutical products (FPPs), mostly HIV/AIDS drugs, manufactured by Ranbaxy on its pre-qualified list and added that a number of generic medicines prequalified by the WHO Pre-Qualification Programme (WHO-PQP), including those of Ranbaxy, have also been approved by stringent regulatory authorities (SRAs). SRAs are those national medicines regulatory authorities which are members, observers or associates of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use.</p><p align="justify">The WHO-PQP statement explained: &quot;In the USA, the term &quot;adulterated&quot; has a specific legal meaning. If a company is not complying with Current Good Manufacturing Practice Regulations (cGMP), any medicines that it manufactures are considered to be &quot;adulterated&quot; under the law. In other words, its medicines are not manufactured under conditions that comply with cGMP. It does not mean that the medicine is necessarily substandard.&quot;</p><p align="justify">Medicines Control Council (MCC) of South Africa too has assured that Ranbaxy drugs were safe and effective. MCC was part of several inspections conducted of Ranbaxy's manufacturing sites. However, the WHO as well as the MCC said that, in 2004, there were problems with Ranbaxy such as with missing data, changes to dates in documentation, and comparative data not being credible which led to many drugs being recalled from the market. But they state that it was fixed over several inspections conducted later. MCC also stated that after FDA banned products from the Paonta Sahib plant of Ranbaxy in 2006, random tests of Ranbaxy drugs on the South African market found no critical deficiencies.</p><p align="justify">According to the WHO, after USFDA issued a warning to Ranbaxy in 2008, WHO-PQP organized several inspection since the Paonta Sahib site also manufactured drugs on WHO's prequalified list. One of these inspections was conducted in November 2008 by a team of 6 inspectors - 3 from WHOPQP, one from the Therapeutic Goods Administration (TGA) of Australia, one from Health Canada and one from MHRA, UK. Some non-compliances were observed and Ranbaxy thereafter submitted documentation describing corrective and preventive actions, which were assessed by the inspection team and found acceptable. &quot;There was no evidence to warrant any further action by WHO-PQP, or indeed by those SRAs who participated in this inspection,&quot; said WHO adding that WHO-PQP has continued to monitor Ranbaxy and all other manufacturers on the WHO list.</p><p align="justify">WHO concluded by giving a list of all the inspections it has conducted along with regulatory authorities from various countries- Swtizerland, France, Hungary, Australia, Kenya, Tanzania South Africa and the UK --since 2000 in Ranbaxy manufacturing sites in Dewas, Mohali and Paonta Sahib.</p><p align="justify">&nbsp;</p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$maxBufferLength = (int) 8192
$file = '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php'
$line = (int) 853
$message = 'Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853'
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 48
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 148]
Code Context
            $response->getStatusCode(),

            ($reasonPhrase ? ' ' . $reasonPhrase : '')

        ));
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67fa0d1f1011a-trace').style.display = (document.getElementById('cakeErr67fa0d1f1011a-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67fa0d1f1011a-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67fa0d1f1011a-code').style.display = (document.getElementById('cakeErr67fa0d1f1011a-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67fa0d1f1011a-context').style.display = (document.getElementById('cakeErr67fa0d1f1011a-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67fa0d1f1011a-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67fa0d1f1011a-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 21571,
		&#039;title&#039; =&gt; &#039;Ranbaxy drugs fine, say WHO and UK regulator -Rema Nagarajan&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Times of India
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;NEW DELHI: &lt;/em&gt;In yet another twist to the Ranbaxy scandal, the drug regulatory authority of the UK government has issued a statement clarifying that they have found no evidence of any Ranbaxy product in the UK market having been &amp;quot;of unacceptable quality&amp;quot;. Last month, WHO had issued a similar statement. It had said that there was no evidence of any of the Ranbaxy products being of unacceptable quality.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Medicines and Healthcare products Regulatory Authority (MHRA) of UK explained that on hearing that Ranbaxy had pleaded guilty to felony charges related to drugs made at two facilities in India it had performed a number of inspections of Ranbaxy sites along with other international regulators including the USFDA and the WHO.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
While some failures to comply with good manufacturing practice (GMP) were reported, the inspections did not find any Ranbaxy products in the UK market being either of unacceptable quality or putting UK patients at risk. The statement clarified: &amp;quot;As part of their investigations the MHRA has tested samples of Ranbaxy products taken from the UK market. All samples met the correct quality specifications.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
MHRA explained how it has been inspecting Ranbaxy sites since 1995 for GMP compliance and elaborated how following USFDA concerns in 2008, MHRA was part of multinational inspection teams which found that while the company complied in general with European Union (EU) GMP they needed to demonstrate continued commitment to improving standards of compliance. Continuing inspections by international teams showed that &amp;quot;the company had made significant progress&amp;quot;.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
According to the MHRA, India is the biggest supplier of Active Pharmaceutical Ingredients (APIs) to the EU and in the last financial year, of the 116 overseas inspections conducted by MHRA, 47 were performed in India and 52 were performed in the US. &amp;quot;There is not a noticeable difference in the number of significant findings identified at UK sites versus those overseas,&amp;quot; added the MHRA. In the UK 23% of UK Marketing Authorisations name an Indian manufacturer and 38% name an Indian API source.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
WHO in its statement explained that it has a number of finished pharmaceutical products (FPPs), mostly HIV/AIDS drugs, manufactured by Ranbaxy on its pre-qualified list and added that a number of generic medicines prequalified by the WHO Pre-Qualification Programme (WHO-PQP), including those of Ranbaxy, have also been approved by stringent regulatory authorities (SRAs). SRAs are those national medicines regulatory authorities which are members, observers or associates of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The WHO-PQP statement explained: &amp;quot;In the USA, the term &amp;quot;adulterated&amp;quot; has a specific legal meaning. If a company is not complying with Current Good Manufacturing Practice Regulations (cGMP), any medicines that it manufactures are considered to be &amp;quot;adulterated&amp;quot; under the law. In other words, its medicines are not manufactured under conditions that comply with cGMP. It does not mean that the medicine is necessarily substandard.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Medicines Control Council (MCC) of South Africa too has assured that Ranbaxy drugs were safe and effective. MCC was part of several inspections conducted of Ranbaxy&#039;s manufacturing sites. However, the WHO as well as the MCC said that, in 2004, there were problems with Ranbaxy such as with missing data, changes to dates in documentation, and comparative data not being credible which led to many drugs being recalled from the market. But they state that it was fixed over several inspections conducted later. MCC also stated that after FDA banned products from the Paonta Sahib plant of Ranbaxy in 2006, random tests of Ranbaxy drugs on the South African market found no critical deficiencies.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
According to the WHO, after USFDA issued a warning to Ranbaxy in 2008, WHO-PQP organized several inspection since the Paonta Sahib site also manufactured drugs on WHO&#039;s prequalified list. One of these inspections was conducted in November 2008 by a team of 6 inspectors - 3 from WHOPQP, one from the Therapeutic Goods Administration (TGA) of Australia, one from Health Canada and one from MHRA, UK. Some non-compliances were observed and Ranbaxy thereafter submitted documentation describing corrective and preventive actions, which were assessed by the inspection team and found acceptable. &amp;quot;There was no evidence to warrant any further action by WHO-PQP, or indeed by those SRAs who participated in this inspection,&amp;quot; said WHO adding that WHO-PQP has continued to monitor Ranbaxy and all other manufacturers on the WHO list.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
WHO concluded by giving a list of all the inspections it has conducted along with regulatory authorities from various countries- Swtizerland, France, Hungary, Australia, Kenya, Tanzania South Africa and the UK --since 2000 in Ranbaxy manufacturing sites in Dewas, Mohali and Paonta Sahib.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;nbsp;
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Times of India, 28 June, 2013, http://timesofindia.indiatimes.com/business/india-business/Ranbaxy-drugs-fine-say-WHO-and-UK-regulator/articleshow/20806204.cms&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;ranbaxy-drugs-fine-say-who-and-uk-regulator-rema-nagarajan-21718&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 21718,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 21571,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Ranbaxy drugs fine, say WHO and UK regulator -Rema Nagarajan&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;medicines,Ranbaxy,Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Times of India



NEW DELHI: In yet another twist to the Ranbaxy scandal, the drug regulatory authority of the UK government has issued a statement clarifying that they have found no evidence of any Ranbaxy product in the UK market...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Times of India&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;NEW DELHI: &lt;/em&gt;In yet another twist to the Ranbaxy scandal, the drug regulatory authority of the UK government has issued a statement clarifying that they have found no evidence of any Ranbaxy product in the UK market having been &amp;quot;of unacceptable quality&amp;quot;. Last month, WHO had issued a similar statement. It had said that there was no evidence of any of the Ranbaxy products being of unacceptable quality.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Medicines and Healthcare products Regulatory Authority (MHRA) of UK explained that on hearing that Ranbaxy had pleaded guilty to felony charges related to drugs made at two facilities in India it had performed a number of inspections of Ranbaxy sites along with other international regulators including the USFDA and the WHO.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;While some failures to comply with good manufacturing practice (GMP) were reported, the inspections did not find any Ranbaxy products in the UK market being either of unacceptable quality or putting UK patients at risk. The statement clarified: &amp;quot;As part of their investigations the MHRA has tested samples of Ranbaxy products taken from the UK market. All samples met the correct quality specifications.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;MHRA explained how it has been inspecting Ranbaxy sites since 1995 for GMP compliance and elaborated how following USFDA concerns in 2008, MHRA was part of multinational inspection teams which found that while the company complied in general with European Union (EU) GMP they needed to demonstrate continued commitment to improving standards of compliance. Continuing inspections by international teams showed that &amp;quot;the company had made significant progress&amp;quot;.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;According to the MHRA, India is the biggest supplier of Active Pharmaceutical Ingredients (APIs) to the EU and in the last financial year, of the 116 overseas inspections conducted by MHRA, 47 were performed in India and 52 were performed in the US. &amp;quot;There is not a noticeable difference in the number of significant findings identified at UK sites versus those overseas,&amp;quot; added the MHRA. In the UK 23% of UK Marketing Authorisations name an Indian manufacturer and 38% name an Indian API source.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;WHO in its statement explained that it has a number of finished pharmaceutical products (FPPs), mostly HIV/AIDS drugs, manufactured by Ranbaxy on its pre-qualified list and added that a number of generic medicines prequalified by the WHO Pre-Qualification Programme (WHO-PQP), including those of Ranbaxy, have also been approved by stringent regulatory authorities (SRAs). SRAs are those national medicines regulatory authorities which are members, observers or associates of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The WHO-PQP statement explained: &amp;quot;In the USA, the term &amp;quot;adulterated&amp;quot; has a specific legal meaning. If a company is not complying with Current Good Manufacturing Practice Regulations (cGMP), any medicines that it manufactures are considered to be &amp;quot;adulterated&amp;quot; under the law. In other words, its medicines are not manufactured under conditions that comply with cGMP. It does not mean that the medicine is necessarily substandard.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Medicines Control Council (MCC) of South Africa too has assured that Ranbaxy drugs were safe and effective. MCC was part of several inspections conducted of Ranbaxy&#039;s manufacturing sites. However, the WHO as well as the MCC said that, in 2004, there were problems with Ranbaxy such as with missing data, changes to dates in documentation, and comparative data not being credible which led to many drugs being recalled from the market. But they state that it was fixed over several inspections conducted later. MCC also stated that after FDA banned products from the Paonta Sahib plant of Ranbaxy in 2006, random tests of Ranbaxy drugs on the South African market found no critical deficiencies.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;According to the WHO, after USFDA issued a warning to Ranbaxy in 2008, WHO-PQP organized several inspection since the Paonta Sahib site also manufactured drugs on WHO&#039;s prequalified list. One of these inspections was conducted in November 2008 by a team of 6 inspectors - 3 from WHOPQP, one from the Therapeutic Goods Administration (TGA) of Australia, one from Health Canada and one from MHRA, UK. Some non-compliances were observed and Ranbaxy thereafter submitted documentation describing corrective and preventive actions, which were assessed by the inspection team and found acceptable. &amp;quot;There was no evidence to warrant any further action by WHO-PQP, or indeed by those SRAs who participated in this inspection,&amp;quot; said WHO adding that WHO-PQP has continued to monitor Ranbaxy and all other manufacturers on the WHO list.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;WHO concluded by giving a list of all the inspections it has conducted along with regulatory authorities from various countries- Swtizerland, France, Hungary, Australia, Kenya, Tanzania South Africa and the UK --since 2000 in Ranbaxy manufacturing sites in Dewas, Mohali and Paonta Sahib.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;nbsp;&lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 21571,
	&#039;title&#039; =&gt; &#039;Ranbaxy drugs fine, say WHO and UK regulator -Rema Nagarajan&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Times of India
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;NEW DELHI: &lt;/em&gt;In yet another twist to the Ranbaxy scandal, the drug regulatory authority of the UK government has issued a statement clarifying that they have found no evidence of any Ranbaxy product in the UK market having been &amp;quot;of unacceptable quality&amp;quot;. Last month, WHO had issued a similar statement. It had said that there was no evidence of any of the Ranbaxy products being of unacceptable quality.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Medicines and Healthcare products Regulatory Authority (MHRA) of UK explained that on hearing that Ranbaxy had pleaded guilty to felony charges related to drugs made at two facilities in India it had performed a number of inspections of Ranbaxy sites along with other international regulators including the USFDA and the WHO.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
While some failures to comply with good manufacturing practice (GMP) were reported, the inspections did not find any Ranbaxy products in the UK market being either of unacceptable quality or putting UK patients at risk. The statement clarified: &amp;quot;As part of their investigations the MHRA has tested samples of Ranbaxy products taken from the UK market. All samples met the correct quality specifications.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
MHRA explained how it has been inspecting Ranbaxy sites since 1995 for GMP compliance and elaborated how following USFDA concerns in 2008, MHRA was part of multinational inspection teams which found that while the company complied in general with European Union (EU) GMP they needed to demonstrate continued commitment to improving standards of compliance. Continuing inspections by international teams showed that &amp;quot;the company had made significant progress&amp;quot;.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
According to the MHRA, India is the biggest supplier of Active Pharmaceutical Ingredients (APIs) to the EU and in the last financial year, of the 116 overseas inspections conducted by MHRA, 47 were performed in India and 52 were performed in the US. &amp;quot;There is not a noticeable difference in the number of significant findings identified at UK sites versus those overseas,&amp;quot; added the MHRA. In the UK 23% of UK Marketing Authorisations name an Indian manufacturer and 38% name an Indian API source.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
WHO in its statement explained that it has a number of finished pharmaceutical products (FPPs), mostly HIV/AIDS drugs, manufactured by Ranbaxy on its pre-qualified list and added that a number of generic medicines prequalified by the WHO Pre-Qualification Programme (WHO-PQP), including those of Ranbaxy, have also been approved by stringent regulatory authorities (SRAs). SRAs are those national medicines regulatory authorities which are members, observers or associates of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The WHO-PQP statement explained: &amp;quot;In the USA, the term &amp;quot;adulterated&amp;quot; has a specific legal meaning. If a company is not complying with Current Good Manufacturing Practice Regulations (cGMP), any medicines that it manufactures are considered to be &amp;quot;adulterated&amp;quot; under the law. In other words, its medicines are not manufactured under conditions that comply with cGMP. It does not mean that the medicine is necessarily substandard.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Medicines Control Council (MCC) of South Africa too has assured that Ranbaxy drugs were safe and effective. MCC was part of several inspections conducted of Ranbaxy&#039;s manufacturing sites. However, the WHO as well as the MCC said that, in 2004, there were problems with Ranbaxy such as with missing data, changes to dates in documentation, and comparative data not being credible which led to many drugs being recalled from the market. But they state that it was fixed over several inspections conducted later. MCC also stated that after FDA banned products from the Paonta Sahib plant of Ranbaxy in 2006, random tests of Ranbaxy drugs on the South African market found no critical deficiencies.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
According to the WHO, after USFDA issued a warning to Ranbaxy in 2008, WHO-PQP organized several inspection since the Paonta Sahib site also manufactured drugs on WHO&#039;s prequalified list. One of these inspections was conducted in November 2008 by a team of 6 inspectors - 3 from WHOPQP, one from the Therapeutic Goods Administration (TGA) of Australia, one from Health Canada and one from MHRA, UK. Some non-compliances were observed and Ranbaxy thereafter submitted documentation describing corrective and preventive actions, which were assessed by the inspection team and found acceptable. &amp;quot;There was no evidence to warrant any further action by WHO-PQP, or indeed by those SRAs who participated in this inspection,&amp;quot; said WHO adding that WHO-PQP has continued to monitor Ranbaxy and all other manufacturers on the WHO list.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
WHO concluded by giving a list of all the inspections it has conducted along with regulatory authorities from various countries- Swtizerland, France, Hungary, Australia, Kenya, Tanzania South Africa and the UK --since 2000 in Ranbaxy manufacturing sites in Dewas, Mohali and Paonta Sahib.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;nbsp;
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Times of India, 28 June, 2013, http://timesofindia.indiatimes.com/business/india-business/Ranbaxy-drugs-fine-say-WHO-and-UK-regulator/articleshow/20806204.cms&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;ranbaxy-drugs-fine-say-who-and-uk-regulator-rema-nagarajan-21718&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 21718,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 21571
$metaTitle = &#039;LATEST NEWS UPDATES | Ranbaxy drugs fine, say WHO and UK regulator -Rema Nagarajan&#039;
$metaKeywords = &#039;medicines,Ranbaxy,Health&#039;
$metaDesc = &#039;
-The Times of India



NEW DELHI: In yet another twist to the Ranbaxy scandal, the drug regulatory authority of the UK government has issued a statement clarifying that they have found no evidence of any Ranbaxy product in the UK market...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Times of India&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;NEW DELHI: &lt;/em&gt;In yet another twist to the Ranbaxy scandal, the drug regulatory authority of the UK government has issued a statement clarifying that they have found no evidence of any Ranbaxy product in the UK market having been &amp;quot;of unacceptable quality&amp;quot;. Last month, WHO had issued a similar statement. It had said that there was no evidence of any of the Ranbaxy products being of unacceptable quality.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Medicines and Healthcare products Regulatory Authority (MHRA) of UK explained that on hearing that Ranbaxy had pleaded guilty to felony charges related to drugs made at two facilities in India it had performed a number of inspections of Ranbaxy sites along with other international regulators including the USFDA and the WHO.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;While some failures to comply with good manufacturing practice (GMP) were reported, the inspections did not find any Ranbaxy products in the UK market being either of unacceptable quality or putting UK patients at risk. The statement clarified: &amp;quot;As part of their investigations the MHRA has tested samples of Ranbaxy products taken from the UK market. All samples met the correct quality specifications.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;MHRA explained how it has been inspecting Ranbaxy sites since 1995 for GMP compliance and elaborated how following USFDA concerns in 2008, MHRA was part of multinational inspection teams which found that while the company complied in general with European Union (EU) GMP they needed to demonstrate continued commitment to improving standards of compliance. Continuing inspections by international teams showed that &amp;quot;the company had made significant progress&amp;quot;.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;According to the MHRA, India is the biggest supplier of Active Pharmaceutical Ingredients (APIs) to the EU and in the last financial year, of the 116 overseas inspections conducted by MHRA, 47 were performed in India and 52 were performed in the US. &amp;quot;There is not a noticeable difference in the number of significant findings identified at UK sites versus those overseas,&amp;quot; added the MHRA. In the UK 23% of UK Marketing Authorisations name an Indian manufacturer and 38% name an Indian API source.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;WHO in its statement explained that it has a number of finished pharmaceutical products (FPPs), mostly HIV/AIDS drugs, manufactured by Ranbaxy on its pre-qualified list and added that a number of generic medicines prequalified by the WHO Pre-Qualification Programme (WHO-PQP), including those of Ranbaxy, have also been approved by stringent regulatory authorities (SRAs). SRAs are those national medicines regulatory authorities which are members, observers or associates of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The WHO-PQP statement explained: &amp;quot;In the USA, the term &amp;quot;adulterated&amp;quot; has a specific legal meaning. If a company is not complying with Current Good Manufacturing Practice Regulations (cGMP), any medicines that it manufactures are considered to be &amp;quot;adulterated&amp;quot; under the law. In other words, its medicines are not manufactured under conditions that comply with cGMP. It does not mean that the medicine is necessarily substandard.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Medicines Control Council (MCC) of South Africa too has assured that Ranbaxy drugs were safe and effective. MCC was part of several inspections conducted of Ranbaxy&#039;s manufacturing sites. However, the WHO as well as the MCC said that, in 2004, there were problems with Ranbaxy such as with missing data, changes to dates in documentation, and comparative data not being credible which led to many drugs being recalled from the market. But they state that it was fixed over several inspections conducted later. MCC also stated that after FDA banned products from the Paonta Sahib plant of Ranbaxy in 2006, random tests of Ranbaxy drugs on the South African market found no critical deficiencies.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;According to the WHO, after USFDA issued a warning to Ranbaxy in 2008, WHO-PQP organized several inspection since the Paonta Sahib site also manufactured drugs on WHO&#039;s prequalified list. One of these inspections was conducted in November 2008 by a team of 6 inspectors - 3 from WHOPQP, one from the Therapeutic Goods Administration (TGA) of Australia, one from Health Canada and one from MHRA, UK. Some non-compliances were observed and Ranbaxy thereafter submitted documentation describing corrective and preventive actions, which were assessed by the inspection team and found acceptable. &amp;quot;There was no evidence to warrant any further action by WHO-PQP, or indeed by those SRAs who participated in this inspection,&amp;quot; said WHO adding that WHO-PQP has continued to monitor Ranbaxy and all other manufacturers on the WHO list.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;WHO concluded by giving a list of all the inspections it has conducted along with regulatory authorities from various countries- Swtizerland, France, Hungary, Australia, Kenya, Tanzania South Africa and the UK --since 2000 in Ranbaxy manufacturing sites in Dewas, Mohali and Paonta Sahib.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;nbsp;&lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/ranbaxy-drugs-fine-say-who-and-uk-regulator-rema-nagarajan-21718.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Ranbaxy drugs fine, say WHO and UK regulator -Rema Nagarajan | Im4change.org</title>
    <meta name="description" content="
-The Times of India



NEW DELHI: In yet another twist to the Ranbaxy scandal, the drug regulatory authority of the UK government has issued a statement clarifying that they have found no evidence of any Ranbaxy product in the UK market..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Ranbaxy drugs fine, say WHO and UK regulator -Rema Nagarajan</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Times of India</div><p align="justify"><br /><em>NEW DELHI: </em>In yet another twist to the Ranbaxy scandal, the drug regulatory authority of the UK government has issued a statement clarifying that they have found no evidence of any Ranbaxy product in the UK market having been &quot;of unacceptable quality&quot;. Last month, WHO had issued a similar statement. It had said that there was no evidence of any of the Ranbaxy products being of unacceptable quality.</p><p align="justify">The Medicines and Healthcare products Regulatory Authority (MHRA) of UK explained that on hearing that Ranbaxy had pleaded guilty to felony charges related to drugs made at two facilities in India it had performed a number of inspections of Ranbaxy sites along with other international regulators including the USFDA and the WHO.</p><p align="justify">While some failures to comply with good manufacturing practice (GMP) were reported, the inspections did not find any Ranbaxy products in the UK market being either of unacceptable quality or putting UK patients at risk. The statement clarified: &quot;As part of their investigations the MHRA has tested samples of Ranbaxy products taken from the UK market. All samples met the correct quality specifications.&quot;</p><p align="justify">MHRA explained how it has been inspecting Ranbaxy sites since 1995 for GMP compliance and elaborated how following USFDA concerns in 2008, MHRA was part of multinational inspection teams which found that while the company complied in general with European Union (EU) GMP they needed to demonstrate continued commitment to improving standards of compliance. Continuing inspections by international teams showed that &quot;the company had made significant progress&quot;.</p><p align="justify">According to the MHRA, India is the biggest supplier of Active Pharmaceutical Ingredients (APIs) to the EU and in the last financial year, of the 116 overseas inspections conducted by MHRA, 47 were performed in India and 52 were performed in the US. &quot;There is not a noticeable difference in the number of significant findings identified at UK sites versus those overseas,&quot; added the MHRA. In the UK 23% of UK Marketing Authorisations name an Indian manufacturer and 38% name an Indian API source.</p><p align="justify">WHO in its statement explained that it has a number of finished pharmaceutical products (FPPs), mostly HIV/AIDS drugs, manufactured by Ranbaxy on its pre-qualified list and added that a number of generic medicines prequalified by the WHO Pre-Qualification Programme (WHO-PQP), including those of Ranbaxy, have also been approved by stringent regulatory authorities (SRAs). SRAs are those national medicines regulatory authorities which are members, observers or associates of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use.</p><p align="justify">The WHO-PQP statement explained: &quot;In the USA, the term &quot;adulterated&quot; has a specific legal meaning. If a company is not complying with Current Good Manufacturing Practice Regulations (cGMP), any medicines that it manufactures are considered to be &quot;adulterated&quot; under the law. In other words, its medicines are not manufactured under conditions that comply with cGMP. It does not mean that the medicine is necessarily substandard.&quot;</p><p align="justify">Medicines Control Council (MCC) of South Africa too has assured that Ranbaxy drugs were safe and effective. MCC was part of several inspections conducted of Ranbaxy's manufacturing sites. However, the WHO as well as the MCC said that, in 2004, there were problems with Ranbaxy such as with missing data, changes to dates in documentation, and comparative data not being credible which led to many drugs being recalled from the market. But they state that it was fixed over several inspections conducted later. MCC also stated that after FDA banned products from the Paonta Sahib plant of Ranbaxy in 2006, random tests of Ranbaxy drugs on the South African market found no critical deficiencies.</p><p align="justify">According to the WHO, after USFDA issued a warning to Ranbaxy in 2008, WHO-PQP organized several inspection since the Paonta Sahib site also manufactured drugs on WHO's prequalified list. One of these inspections was conducted in November 2008 by a team of 6 inspectors - 3 from WHOPQP, one from the Therapeutic Goods Administration (TGA) of Australia, one from Health Canada and one from MHRA, UK. Some non-compliances were observed and Ranbaxy thereafter submitted documentation describing corrective and preventive actions, which were assessed by the inspection team and found acceptable. &quot;There was no evidence to warrant any further action by WHO-PQP, or indeed by those SRAs who participated in this inspection,&quot; said WHO adding that WHO-PQP has continued to monitor Ranbaxy and all other manufacturers on the WHO list.</p><p align="justify">WHO concluded by giving a list of all the inspections it has conducted along with regulatory authorities from various countries- Swtizerland, France, Hungary, Australia, Kenya, Tanzania South Africa and the UK --since 2000 in Ranbaxy manufacturing sites in Dewas, Mohali and Paonta Sahib.</p><p align="justify">&nbsp;</p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$reasonPhrase = 'OK'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitStatusLine() - CORE/src/Http/ResponseEmitter.php, line 148
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 54
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 181]
Code Context
                    $value

                ), $first);

                $first = false;
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67fa0d1f1011a-trace').style.display = (document.getElementById('cakeErr67fa0d1f1011a-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67fa0d1f1011a-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67fa0d1f1011a-code').style.display = (document.getElementById('cakeErr67fa0d1f1011a-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67fa0d1f1011a-context').style.display = (document.getElementById('cakeErr67fa0d1f1011a-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67fa0d1f1011a-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67fa0d1f1011a-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 21571,
		&#039;title&#039; =&gt; &#039;Ranbaxy drugs fine, say WHO and UK regulator -Rema Nagarajan&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Times of India
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;NEW DELHI: &lt;/em&gt;In yet another twist to the Ranbaxy scandal, the drug regulatory authority of the UK government has issued a statement clarifying that they have found no evidence of any Ranbaxy product in the UK market having been &amp;quot;of unacceptable quality&amp;quot;. Last month, WHO had issued a similar statement. It had said that there was no evidence of any of the Ranbaxy products being of unacceptable quality.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Medicines and Healthcare products Regulatory Authority (MHRA) of UK explained that on hearing that Ranbaxy had pleaded guilty to felony charges related to drugs made at two facilities in India it had performed a number of inspections of Ranbaxy sites along with other international regulators including the USFDA and the WHO.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
While some failures to comply with good manufacturing practice (GMP) were reported, the inspections did not find any Ranbaxy products in the UK market being either of unacceptable quality or putting UK patients at risk. The statement clarified: &amp;quot;As part of their investigations the MHRA has tested samples of Ranbaxy products taken from the UK market. All samples met the correct quality specifications.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
MHRA explained how it has been inspecting Ranbaxy sites since 1995 for GMP compliance and elaborated how following USFDA concerns in 2008, MHRA was part of multinational inspection teams which found that while the company complied in general with European Union (EU) GMP they needed to demonstrate continued commitment to improving standards of compliance. Continuing inspections by international teams showed that &amp;quot;the company had made significant progress&amp;quot;.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
According to the MHRA, India is the biggest supplier of Active Pharmaceutical Ingredients (APIs) to the EU and in the last financial year, of the 116 overseas inspections conducted by MHRA, 47 were performed in India and 52 were performed in the US. &amp;quot;There is not a noticeable difference in the number of significant findings identified at UK sites versus those overseas,&amp;quot; added the MHRA. In the UK 23% of UK Marketing Authorisations name an Indian manufacturer and 38% name an Indian API source.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
WHO in its statement explained that it has a number of finished pharmaceutical products (FPPs), mostly HIV/AIDS drugs, manufactured by Ranbaxy on its pre-qualified list and added that a number of generic medicines prequalified by the WHO Pre-Qualification Programme (WHO-PQP), including those of Ranbaxy, have also been approved by stringent regulatory authorities (SRAs). SRAs are those national medicines regulatory authorities which are members, observers or associates of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The WHO-PQP statement explained: &amp;quot;In the USA, the term &amp;quot;adulterated&amp;quot; has a specific legal meaning. If a company is not complying with Current Good Manufacturing Practice Regulations (cGMP), any medicines that it manufactures are considered to be &amp;quot;adulterated&amp;quot; under the law. In other words, its medicines are not manufactured under conditions that comply with cGMP. It does not mean that the medicine is necessarily substandard.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Medicines Control Council (MCC) of South Africa too has assured that Ranbaxy drugs were safe and effective. MCC was part of several inspections conducted of Ranbaxy&#039;s manufacturing sites. However, the WHO as well as the MCC said that, in 2004, there were problems with Ranbaxy such as with missing data, changes to dates in documentation, and comparative data not being credible which led to many drugs being recalled from the market. But they state that it was fixed over several inspections conducted later. MCC also stated that after FDA banned products from the Paonta Sahib plant of Ranbaxy in 2006, random tests of Ranbaxy drugs on the South African market found no critical deficiencies.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
According to the WHO, after USFDA issued a warning to Ranbaxy in 2008, WHO-PQP organized several inspection since the Paonta Sahib site also manufactured drugs on WHO&#039;s prequalified list. One of these inspections was conducted in November 2008 by a team of 6 inspectors - 3 from WHOPQP, one from the Therapeutic Goods Administration (TGA) of Australia, one from Health Canada and one from MHRA, UK. Some non-compliances were observed and Ranbaxy thereafter submitted documentation describing corrective and preventive actions, which were assessed by the inspection team and found acceptable. &amp;quot;There was no evidence to warrant any further action by WHO-PQP, or indeed by those SRAs who participated in this inspection,&amp;quot; said WHO adding that WHO-PQP has continued to monitor Ranbaxy and all other manufacturers on the WHO list.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
WHO concluded by giving a list of all the inspections it has conducted along with regulatory authorities from various countries- Swtizerland, France, Hungary, Australia, Kenya, Tanzania South Africa and the UK --since 2000 in Ranbaxy manufacturing sites in Dewas, Mohali and Paonta Sahib.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;nbsp;
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Times of India, 28 June, 2013, http://timesofindia.indiatimes.com/business/india-business/Ranbaxy-drugs-fine-say-WHO-and-UK-regulator/articleshow/20806204.cms&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;ranbaxy-drugs-fine-say-who-and-uk-regulator-rema-nagarajan-21718&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 21718,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 21571,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Ranbaxy drugs fine, say WHO and UK regulator -Rema Nagarajan&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;medicines,Ranbaxy,Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Times of India



NEW DELHI: In yet another twist to the Ranbaxy scandal, the drug regulatory authority of the UK government has issued a statement clarifying that they have found no evidence of any Ranbaxy product in the UK market...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Times of India&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;NEW DELHI: &lt;/em&gt;In yet another twist to the Ranbaxy scandal, the drug regulatory authority of the UK government has issued a statement clarifying that they have found no evidence of any Ranbaxy product in the UK market having been &amp;quot;of unacceptable quality&amp;quot;. Last month, WHO had issued a similar statement. It had said that there was no evidence of any of the Ranbaxy products being of unacceptable quality.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Medicines and Healthcare products Regulatory Authority (MHRA) of UK explained that on hearing that Ranbaxy had pleaded guilty to felony charges related to drugs made at two facilities in India it had performed a number of inspections of Ranbaxy sites along with other international regulators including the USFDA and the WHO.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;While some failures to comply with good manufacturing practice (GMP) were reported, the inspections did not find any Ranbaxy products in the UK market being either of unacceptable quality or putting UK patients at risk. The statement clarified: &amp;quot;As part of their investigations the MHRA has tested samples of Ranbaxy products taken from the UK market. All samples met the correct quality specifications.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;MHRA explained how it has been inspecting Ranbaxy sites since 1995 for GMP compliance and elaborated how following USFDA concerns in 2008, MHRA was part of multinational inspection teams which found that while the company complied in general with European Union (EU) GMP they needed to demonstrate continued commitment to improving standards of compliance. Continuing inspections by international teams showed that &amp;quot;the company had made significant progress&amp;quot;.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;According to the MHRA, India is the biggest supplier of Active Pharmaceutical Ingredients (APIs) to the EU and in the last financial year, of the 116 overseas inspections conducted by MHRA, 47 were performed in India and 52 were performed in the US. &amp;quot;There is not a noticeable difference in the number of significant findings identified at UK sites versus those overseas,&amp;quot; added the MHRA. In the UK 23% of UK Marketing Authorisations name an Indian manufacturer and 38% name an Indian API source.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;WHO in its statement explained that it has a number of finished pharmaceutical products (FPPs), mostly HIV/AIDS drugs, manufactured by Ranbaxy on its pre-qualified list and added that a number of generic medicines prequalified by the WHO Pre-Qualification Programme (WHO-PQP), including those of Ranbaxy, have also been approved by stringent regulatory authorities (SRAs). SRAs are those national medicines regulatory authorities which are members, observers or associates of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The WHO-PQP statement explained: &amp;quot;In the USA, the term &amp;quot;adulterated&amp;quot; has a specific legal meaning. If a company is not complying with Current Good Manufacturing Practice Regulations (cGMP), any medicines that it manufactures are considered to be &amp;quot;adulterated&amp;quot; under the law. In other words, its medicines are not manufactured under conditions that comply with cGMP. It does not mean that the medicine is necessarily substandard.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Medicines Control Council (MCC) of South Africa too has assured that Ranbaxy drugs were safe and effective. MCC was part of several inspections conducted of Ranbaxy&#039;s manufacturing sites. However, the WHO as well as the MCC said that, in 2004, there were problems with Ranbaxy such as with missing data, changes to dates in documentation, and comparative data not being credible which led to many drugs being recalled from the market. But they state that it was fixed over several inspections conducted later. MCC also stated that after FDA banned products from the Paonta Sahib plant of Ranbaxy in 2006, random tests of Ranbaxy drugs on the South African market found no critical deficiencies.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;According to the WHO, after USFDA issued a warning to Ranbaxy in 2008, WHO-PQP organized several inspection since the Paonta Sahib site also manufactured drugs on WHO&#039;s prequalified list. One of these inspections was conducted in November 2008 by a team of 6 inspectors - 3 from WHOPQP, one from the Therapeutic Goods Administration (TGA) of Australia, one from Health Canada and one from MHRA, UK. Some non-compliances were observed and Ranbaxy thereafter submitted documentation describing corrective and preventive actions, which were assessed by the inspection team and found acceptable. &amp;quot;There was no evidence to warrant any further action by WHO-PQP, or indeed by those SRAs who participated in this inspection,&amp;quot; said WHO adding that WHO-PQP has continued to monitor Ranbaxy and all other manufacturers on the WHO list.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;WHO concluded by giving a list of all the inspections it has conducted along with regulatory authorities from various countries- Swtizerland, France, Hungary, Australia, Kenya, Tanzania South Africa and the UK --since 2000 in Ranbaxy manufacturing sites in Dewas, Mohali and Paonta Sahib.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;nbsp;&lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 21571,
	&#039;title&#039; =&gt; &#039;Ranbaxy drugs fine, say WHO and UK regulator -Rema Nagarajan&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Times of India
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;NEW DELHI: &lt;/em&gt;In yet another twist to the Ranbaxy scandal, the drug regulatory authority of the UK government has issued a statement clarifying that they have found no evidence of any Ranbaxy product in the UK market having been &amp;quot;of unacceptable quality&amp;quot;. Last month, WHO had issued a similar statement. It had said that there was no evidence of any of the Ranbaxy products being of unacceptable quality.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Medicines and Healthcare products Regulatory Authority (MHRA) of UK explained that on hearing that Ranbaxy had pleaded guilty to felony charges related to drugs made at two facilities in India it had performed a number of inspections of Ranbaxy sites along with other international regulators including the USFDA and the WHO.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
While some failures to comply with good manufacturing practice (GMP) were reported, the inspections did not find any Ranbaxy products in the UK market being either of unacceptable quality or putting UK patients at risk. The statement clarified: &amp;quot;As part of their investigations the MHRA has tested samples of Ranbaxy products taken from the UK market. All samples met the correct quality specifications.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
MHRA explained how it has been inspecting Ranbaxy sites since 1995 for GMP compliance and elaborated how following USFDA concerns in 2008, MHRA was part of multinational inspection teams which found that while the company complied in general with European Union (EU) GMP they needed to demonstrate continued commitment to improving standards of compliance. Continuing inspections by international teams showed that &amp;quot;the company had made significant progress&amp;quot;.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
According to the MHRA, India is the biggest supplier of Active Pharmaceutical Ingredients (APIs) to the EU and in the last financial year, of the 116 overseas inspections conducted by MHRA, 47 were performed in India and 52 were performed in the US. &amp;quot;There is not a noticeable difference in the number of significant findings identified at UK sites versus those overseas,&amp;quot; added the MHRA. In the UK 23% of UK Marketing Authorisations name an Indian manufacturer and 38% name an Indian API source.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
WHO in its statement explained that it has a number of finished pharmaceutical products (FPPs), mostly HIV/AIDS drugs, manufactured by Ranbaxy on its pre-qualified list and added that a number of generic medicines prequalified by the WHO Pre-Qualification Programme (WHO-PQP), including those of Ranbaxy, have also been approved by stringent regulatory authorities (SRAs). SRAs are those national medicines regulatory authorities which are members, observers or associates of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The WHO-PQP statement explained: &amp;quot;In the USA, the term &amp;quot;adulterated&amp;quot; has a specific legal meaning. If a company is not complying with Current Good Manufacturing Practice Regulations (cGMP), any medicines that it manufactures are considered to be &amp;quot;adulterated&amp;quot; under the law. In other words, its medicines are not manufactured under conditions that comply with cGMP. It does not mean that the medicine is necessarily substandard.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Medicines Control Council (MCC) of South Africa too has assured that Ranbaxy drugs were safe and effective. MCC was part of several inspections conducted of Ranbaxy&#039;s manufacturing sites. However, the WHO as well as the MCC said that, in 2004, there were problems with Ranbaxy such as with missing data, changes to dates in documentation, and comparative data not being credible which led to many drugs being recalled from the market. But they state that it was fixed over several inspections conducted later. MCC also stated that after FDA banned products from the Paonta Sahib plant of Ranbaxy in 2006, random tests of Ranbaxy drugs on the South African market found no critical deficiencies.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
According to the WHO, after USFDA issued a warning to Ranbaxy in 2008, WHO-PQP organized several inspection since the Paonta Sahib site also manufactured drugs on WHO&#039;s prequalified list. One of these inspections was conducted in November 2008 by a team of 6 inspectors - 3 from WHOPQP, one from the Therapeutic Goods Administration (TGA) of Australia, one from Health Canada and one from MHRA, UK. Some non-compliances were observed and Ranbaxy thereafter submitted documentation describing corrective and preventive actions, which were assessed by the inspection team and found acceptable. &amp;quot;There was no evidence to warrant any further action by WHO-PQP, or indeed by those SRAs who participated in this inspection,&amp;quot; said WHO adding that WHO-PQP has continued to monitor Ranbaxy and all other manufacturers on the WHO list.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
WHO concluded by giving a list of all the inspections it has conducted along with regulatory authorities from various countries- Swtizerland, France, Hungary, Australia, Kenya, Tanzania South Africa and the UK --since 2000 in Ranbaxy manufacturing sites in Dewas, Mohali and Paonta Sahib.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;nbsp;
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Times of India, 28 June, 2013, http://timesofindia.indiatimes.com/business/india-business/Ranbaxy-drugs-fine-say-WHO-and-UK-regulator/articleshow/20806204.cms&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;ranbaxy-drugs-fine-say-who-and-uk-regulator-rema-nagarajan-21718&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 21718,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 21571
$metaTitle = &#039;LATEST NEWS UPDATES | Ranbaxy drugs fine, say WHO and UK regulator -Rema Nagarajan&#039;
$metaKeywords = &#039;medicines,Ranbaxy,Health&#039;
$metaDesc = &#039;
-The Times of India



NEW DELHI: In yet another twist to the Ranbaxy scandal, the drug regulatory authority of the UK government has issued a statement clarifying that they have found no evidence of any Ranbaxy product in the UK market...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Times of India&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;NEW DELHI: &lt;/em&gt;In yet another twist to the Ranbaxy scandal, the drug regulatory authority of the UK government has issued a statement clarifying that they have found no evidence of any Ranbaxy product in the UK market having been &amp;quot;of unacceptable quality&amp;quot;. Last month, WHO had issued a similar statement. It had said that there was no evidence of any of the Ranbaxy products being of unacceptable quality.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Medicines and Healthcare products Regulatory Authority (MHRA) of UK explained that on hearing that Ranbaxy had pleaded guilty to felony charges related to drugs made at two facilities in India it had performed a number of inspections of Ranbaxy sites along with other international regulators including the USFDA and the WHO.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;While some failures to comply with good manufacturing practice (GMP) were reported, the inspections did not find any Ranbaxy products in the UK market being either of unacceptable quality or putting UK patients at risk. The statement clarified: &amp;quot;As part of their investigations the MHRA has tested samples of Ranbaxy products taken from the UK market. All samples met the correct quality specifications.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;MHRA explained how it has been inspecting Ranbaxy sites since 1995 for GMP compliance and elaborated how following USFDA concerns in 2008, MHRA was part of multinational inspection teams which found that while the company complied in general with European Union (EU) GMP they needed to demonstrate continued commitment to improving standards of compliance. Continuing inspections by international teams showed that &amp;quot;the company had made significant progress&amp;quot;.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;According to the MHRA, India is the biggest supplier of Active Pharmaceutical Ingredients (APIs) to the EU and in the last financial year, of the 116 overseas inspections conducted by MHRA, 47 were performed in India and 52 were performed in the US. &amp;quot;There is not a noticeable difference in the number of significant findings identified at UK sites versus those overseas,&amp;quot; added the MHRA. In the UK 23% of UK Marketing Authorisations name an Indian manufacturer and 38% name an Indian API source.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;WHO in its statement explained that it has a number of finished pharmaceutical products (FPPs), mostly HIV/AIDS drugs, manufactured by Ranbaxy on its pre-qualified list and added that a number of generic medicines prequalified by the WHO Pre-Qualification Programme (WHO-PQP), including those of Ranbaxy, have also been approved by stringent regulatory authorities (SRAs). SRAs are those national medicines regulatory authorities which are members, observers or associates of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The WHO-PQP statement explained: &amp;quot;In the USA, the term &amp;quot;adulterated&amp;quot; has a specific legal meaning. If a company is not complying with Current Good Manufacturing Practice Regulations (cGMP), any medicines that it manufactures are considered to be &amp;quot;adulterated&amp;quot; under the law. In other words, its medicines are not manufactured under conditions that comply with cGMP. It does not mean that the medicine is necessarily substandard.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Medicines Control Council (MCC) of South Africa too has assured that Ranbaxy drugs were safe and effective. MCC was part of several inspections conducted of Ranbaxy&#039;s manufacturing sites. However, the WHO as well as the MCC said that, in 2004, there were problems with Ranbaxy such as with missing data, changes to dates in documentation, and comparative data not being credible which led to many drugs being recalled from the market. But they state that it was fixed over several inspections conducted later. MCC also stated that after FDA banned products from the Paonta Sahib plant of Ranbaxy in 2006, random tests of Ranbaxy drugs on the South African market found no critical deficiencies.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;According to the WHO, after USFDA issued a warning to Ranbaxy in 2008, WHO-PQP organized several inspection since the Paonta Sahib site also manufactured drugs on WHO&#039;s prequalified list. One of these inspections was conducted in November 2008 by a team of 6 inspectors - 3 from WHOPQP, one from the Therapeutic Goods Administration (TGA) of Australia, one from Health Canada and one from MHRA, UK. Some non-compliances were observed and Ranbaxy thereafter submitted documentation describing corrective and preventive actions, which were assessed by the inspection team and found acceptable. &amp;quot;There was no evidence to warrant any further action by WHO-PQP, or indeed by those SRAs who participated in this inspection,&amp;quot; said WHO adding that WHO-PQP has continued to monitor Ranbaxy and all other manufacturers on the WHO list.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;WHO concluded by giving a list of all the inspections it has conducted along with regulatory authorities from various countries- Swtizerland, France, Hungary, Australia, Kenya, Tanzania South Africa and the UK --since 2000 in Ranbaxy manufacturing sites in Dewas, Mohali and Paonta Sahib.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;nbsp;&lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/ranbaxy-drugs-fine-say-who-and-uk-regulator-rema-nagarajan-21718.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Ranbaxy drugs fine, say WHO and UK regulator -Rema Nagarajan | Im4change.org</title>
    <meta name="description" content="
-The Times of India



NEW DELHI: In yet another twist to the Ranbaxy scandal, the drug regulatory authority of the UK government has issued a statement clarifying that they have found no evidence of any Ranbaxy product in the UK market..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Ranbaxy drugs fine, say WHO and UK regulator -Rema Nagarajan</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Times of India</div><p align="justify"><br /><em>NEW DELHI: </em>In yet another twist to the Ranbaxy scandal, the drug regulatory authority of the UK government has issued a statement clarifying that they have found no evidence of any Ranbaxy product in the UK market having been &quot;of unacceptable quality&quot;. Last month, WHO had issued a similar statement. It had said that there was no evidence of any of the Ranbaxy products being of unacceptable quality.</p><p align="justify">The Medicines and Healthcare products Regulatory Authority (MHRA) of UK explained that on hearing that Ranbaxy had pleaded guilty to felony charges related to drugs made at two facilities in India it had performed a number of inspections of Ranbaxy sites along with other international regulators including the USFDA and the WHO.</p><p align="justify">While some failures to comply with good manufacturing practice (GMP) were reported, the inspections did not find any Ranbaxy products in the UK market being either of unacceptable quality or putting UK patients at risk. The statement clarified: &quot;As part of their investigations the MHRA has tested samples of Ranbaxy products taken from the UK market. All samples met the correct quality specifications.&quot;</p><p align="justify">MHRA explained how it has been inspecting Ranbaxy sites since 1995 for GMP compliance and elaborated how following USFDA concerns in 2008, MHRA was part of multinational inspection teams which found that while the company complied in general with European Union (EU) GMP they needed to demonstrate continued commitment to improving standards of compliance. Continuing inspections by international teams showed that &quot;the company had made significant progress&quot;.</p><p align="justify">According to the MHRA, India is the biggest supplier of Active Pharmaceutical Ingredients (APIs) to the EU and in the last financial year, of the 116 overseas inspections conducted by MHRA, 47 were performed in India and 52 were performed in the US. &quot;There is not a noticeable difference in the number of significant findings identified at UK sites versus those overseas,&quot; added the MHRA. In the UK 23% of UK Marketing Authorisations name an Indian manufacturer and 38% name an Indian API source.</p><p align="justify">WHO in its statement explained that it has a number of finished pharmaceutical products (FPPs), mostly HIV/AIDS drugs, manufactured by Ranbaxy on its pre-qualified list and added that a number of generic medicines prequalified by the WHO Pre-Qualification Programme (WHO-PQP), including those of Ranbaxy, have also been approved by stringent regulatory authorities (SRAs). SRAs are those national medicines regulatory authorities which are members, observers or associates of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use.</p><p align="justify">The WHO-PQP statement explained: &quot;In the USA, the term &quot;adulterated&quot; has a specific legal meaning. If a company is not complying with Current Good Manufacturing Practice Regulations (cGMP), any medicines that it manufactures are considered to be &quot;adulterated&quot; under the law. In other words, its medicines are not manufactured under conditions that comply with cGMP. It does not mean that the medicine is necessarily substandard.&quot;</p><p align="justify">Medicines Control Council (MCC) of South Africa too has assured that Ranbaxy drugs were safe and effective. MCC was part of several inspections conducted of Ranbaxy's manufacturing sites. However, the WHO as well as the MCC said that, in 2004, there were problems with Ranbaxy such as with missing data, changes to dates in documentation, and comparative data not being credible which led to many drugs being recalled from the market. But they state that it was fixed over several inspections conducted later. MCC also stated that after FDA banned products from the Paonta Sahib plant of Ranbaxy in 2006, random tests of Ranbaxy drugs on the South African market found no critical deficiencies.</p><p align="justify">According to the WHO, after USFDA issued a warning to Ranbaxy in 2008, WHO-PQP organized several inspection since the Paonta Sahib site also manufactured drugs on WHO's prequalified list. One of these inspections was conducted in November 2008 by a team of 6 inspectors - 3 from WHOPQP, one from the Therapeutic Goods Administration (TGA) of Australia, one from Health Canada and one from MHRA, UK. Some non-compliances were observed and Ranbaxy thereafter submitted documentation describing corrective and preventive actions, which were assessed by the inspection team and found acceptable. &quot;There was no evidence to warrant any further action by WHO-PQP, or indeed by those SRAs who participated in this inspection,&quot; said WHO adding that WHO-PQP has continued to monitor Ranbaxy and all other manufacturers on the WHO list.</p><p align="justify">WHO concluded by giving a list of all the inspections it has conducted along with regulatory authorities from various countries- Swtizerland, France, Hungary, Australia, Kenya, Tanzania South Africa and the UK --since 2000 in Ranbaxy manufacturing sites in Dewas, Mohali and Paonta Sahib.</p><p align="justify">&nbsp;</p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$cookies = []
$values = [
	(int) 0 => 'text/html; charset=UTF-8'
]
$name = 'Content-Type'
$first = true
$value = 'text/html; charset=UTF-8'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitHeaders() - CORE/src/Http/ResponseEmitter.php, line 181
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 55
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

<head>

    <link rel="canonical" href="<?php echo Configure::read('SITE_URL'); ?><?php echo $urlPrefix;?><?php echo $article_current->category->slug; ?>/<?php echo $article_current->seo_url; ?>.html"/>

    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>

$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp'
$dataForView = [
	'article_current' => object(App\Model\Entity\Article) {

		'id' => (int) 21571,
		'title' => 'Ranbaxy drugs fine, say WHO and UK regulator -Rema Nagarajan',
		'subheading' => '',
		'description' => '<div align="justify">
-The Times of India
</div>
<p align="justify">
<br />
<em>NEW DELHI: </em>In yet another twist to the Ranbaxy scandal, the drug regulatory authority of the UK government has issued a statement clarifying that they have found no evidence of any Ranbaxy product in the UK market having been &quot;of unacceptable quality&quot;. Last month, WHO had issued a similar statement. It had said that there was no evidence of any of the Ranbaxy products being of unacceptable quality.
</p>
<p align="justify">
The Medicines and Healthcare products Regulatory Authority (MHRA) of UK explained that on hearing that Ranbaxy had pleaded guilty to felony charges related to drugs made at two facilities in India it had performed a number of inspections of Ranbaxy sites along with other international regulators including the USFDA and the WHO.
</p>
<p align="justify">
While some failures to comply with good manufacturing practice (GMP) were reported, the inspections did not find any Ranbaxy products in the UK market being either of unacceptable quality or putting UK patients at risk. The statement clarified: &quot;As part of their investigations the MHRA has tested samples of Ranbaxy products taken from the UK market. All samples met the correct quality specifications.&quot;
</p>
<p align="justify">
MHRA explained how it has been inspecting Ranbaxy sites since 1995 for GMP compliance and elaborated how following USFDA concerns in 2008, MHRA was part of multinational inspection teams which found that while the company complied in general with European Union (EU) GMP they needed to demonstrate continued commitment to improving standards of compliance. Continuing inspections by international teams showed that &quot;the company had made significant progress&quot;.
</p>
<p align="justify">
According to the MHRA, India is the biggest supplier of Active Pharmaceutical Ingredients (APIs) to the EU and in the last financial year, of the 116 overseas inspections conducted by MHRA, 47 were performed in India and 52 were performed in the US. &quot;There is not a noticeable difference in the number of significant findings identified at UK sites versus those overseas,&quot; added the MHRA. In the UK 23% of UK Marketing Authorisations name an Indian manufacturer and 38% name an Indian API source.
</p>
<p align="justify">
WHO in its statement explained that it has a number of finished pharmaceutical products (FPPs), mostly HIV/AIDS drugs, manufactured by Ranbaxy on its pre-qualified list and added that a number of generic medicines prequalified by the WHO Pre-Qualification Programme (WHO-PQP), including those of Ranbaxy, have also been approved by stringent regulatory authorities (SRAs). SRAs are those national medicines regulatory authorities which are members, observers or associates of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use.
</p>
<p align="justify">
The WHO-PQP statement explained: &quot;In the USA, the term &quot;adulterated&quot; has a specific legal meaning. If a company is not complying with Current Good Manufacturing Practice Regulations (cGMP), any medicines that it manufactures are considered to be &quot;adulterated&quot; under the law. In other words, its medicines are not manufactured under conditions that comply with cGMP. It does not mean that the medicine is necessarily substandard.&quot;
</p>
<p align="justify">
Medicines Control Council (MCC) of South Africa too has assured that Ranbaxy drugs were safe and effective. MCC was part of several inspections conducted of Ranbaxy's manufacturing sites. However, the WHO as well as the MCC said that, in 2004, there were problems with Ranbaxy such as with missing data, changes to dates in documentation, and comparative data not being credible which led to many drugs being recalled from the market. But they state that it was fixed over several inspections conducted later. MCC also stated that after FDA banned products from the Paonta Sahib plant of Ranbaxy in 2006, random tests of Ranbaxy drugs on the South African market found no critical deficiencies.
</p>
<p align="justify">
According to the WHO, after USFDA issued a warning to Ranbaxy in 2008, WHO-PQP organized several inspection since the Paonta Sahib site also manufactured drugs on WHO's prequalified list. One of these inspections was conducted in November 2008 by a team of 6 inspectors - 3 from WHOPQP, one from the Therapeutic Goods Administration (TGA) of Australia, one from Health Canada and one from MHRA, UK. Some non-compliances were observed and Ranbaxy thereafter submitted documentation describing corrective and preventive actions, which were assessed by the inspection team and found acceptable. &quot;There was no evidence to warrant any further action by WHO-PQP, or indeed by those SRAs who participated in this inspection,&quot; said WHO adding that WHO-PQP has continued to monitor Ranbaxy and all other manufacturers on the WHO list.
</p>
<p align="justify">
WHO concluded by giving a list of all the inspections it has conducted along with regulatory authorities from various countries- Swtizerland, France, Hungary, Australia, Kenya, Tanzania South Africa and the UK --since 2000 in Ranbaxy manufacturing sites in Dewas, Mohali and Paonta Sahib.
</p>
<p align="justify">
&nbsp;
</p>',
		'credit_writer' => 'The Times of India, 28 June, 2013, http://timesofindia.indiatimes.com/business/india-business/Ranbaxy-drugs-fine-say-WHO-and-UK-regulator/articleshow/20806204.cms',
		'article_img' => '',
		'article_img_thumb' => '',
		'status' => (int) 1,
		'show_on_home' => (int) 1,
		'lang' => 'EN',
		'category_id' => (int) 16,
		'tag_keyword' => '',
		'seo_url' => 'ranbaxy-drugs-fine-say-who-and-uk-regulator-rema-nagarajan-21718',
		'meta_title' => null,
		'meta_keywords' => null,
		'meta_description' => null,
		'noindex' => (int) 0,
		'publish_date' => object(Cake\I18n\FrozenDate) {},
		'most_visit_section_id' => null,
		'article_big_img' => null,
		'liveid' => (int) 21718,
		'created' => object(Cake\I18n\FrozenTime) {},
		'modified' => object(Cake\I18n\FrozenTime) {},
		'edate' => '',
		'tags' => [
			[maximum depth reached]
		],
		'category' => object(App\Model\Entity\Category) {},
		'[new]' => false,
		'[accessible]' => [
			[maximum depth reached]
		],
		'[dirty]' => [[maximum depth reached]],
		'[original]' => [[maximum depth reached]],
		'[virtual]' => [[maximum depth reached]],
		'[hasErrors]' => false,
		'[errors]' => [[maximum depth reached]],
		'[invalid]' => [[maximum depth reached]],
		'[repository]' => 'Articles'
	
	},
	'articleid' => (int) 21571,
	'metaTitle' => 'LATEST NEWS UPDATES | Ranbaxy drugs fine, say WHO and UK regulator -Rema Nagarajan',
	'metaKeywords' => 'medicines,Ranbaxy,Health',
	'metaDesc' => '
-The Times of India



NEW DELHI: In yet another twist to the Ranbaxy scandal, the drug regulatory authority of the UK government has issued a statement clarifying that they have found no evidence of any Ranbaxy product in the UK market...',
	'disp' => '<div align="justify">-The Times of India</div><p align="justify"><br /><em>NEW DELHI: </em>In yet another twist to the Ranbaxy scandal, the drug regulatory authority of the UK government has issued a statement clarifying that they have found no evidence of any Ranbaxy product in the UK market having been &quot;of unacceptable quality&quot;. Last month, WHO had issued a similar statement. It had said that there was no evidence of any of the Ranbaxy products being of unacceptable quality.</p><p align="justify">The Medicines and Healthcare products Regulatory Authority (MHRA) of UK explained that on hearing that Ranbaxy had pleaded guilty to felony charges related to drugs made at two facilities in India it had performed a number of inspections of Ranbaxy sites along with other international regulators including the USFDA and the WHO.</p><p align="justify">While some failures to comply with good manufacturing practice (GMP) were reported, the inspections did not find any Ranbaxy products in the UK market being either of unacceptable quality or putting UK patients at risk. The statement clarified: &quot;As part of their investigations the MHRA has tested samples of Ranbaxy products taken from the UK market. All samples met the correct quality specifications.&quot;</p><p align="justify">MHRA explained how it has been inspecting Ranbaxy sites since 1995 for GMP compliance and elaborated how following USFDA concerns in 2008, MHRA was part of multinational inspection teams which found that while the company complied in general with European Union (EU) GMP they needed to demonstrate continued commitment to improving standards of compliance. Continuing inspections by international teams showed that &quot;the company had made significant progress&quot;.</p><p align="justify">According to the MHRA, India is the biggest supplier of Active Pharmaceutical Ingredients (APIs) to the EU and in the last financial year, of the 116 overseas inspections conducted by MHRA, 47 were performed in India and 52 were performed in the US. &quot;There is not a noticeable difference in the number of significant findings identified at UK sites versus those overseas,&quot; added the MHRA. In the UK 23% of UK Marketing Authorisations name an Indian manufacturer and 38% name an Indian API source.</p><p align="justify">WHO in its statement explained that it has a number of finished pharmaceutical products (FPPs), mostly HIV/AIDS drugs, manufactured by Ranbaxy on its pre-qualified list and added that a number of generic medicines prequalified by the WHO Pre-Qualification Programme (WHO-PQP), including those of Ranbaxy, have also been approved by stringent regulatory authorities (SRAs). SRAs are those national medicines regulatory authorities which are members, observers or associates of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use.</p><p align="justify">The WHO-PQP statement explained: &quot;In the USA, the term &quot;adulterated&quot; has a specific legal meaning. If a company is not complying with Current Good Manufacturing Practice Regulations (cGMP), any medicines that it manufactures are considered to be &quot;adulterated&quot; under the law. In other words, its medicines are not manufactured under conditions that comply with cGMP. It does not mean that the medicine is necessarily substandard.&quot;</p><p align="justify">Medicines Control Council (MCC) of South Africa too has assured that Ranbaxy drugs were safe and effective. MCC was part of several inspections conducted of Ranbaxy's manufacturing sites. However, the WHO as well as the MCC said that, in 2004, there were problems with Ranbaxy such as with missing data, changes to dates in documentation, and comparative data not being credible which led to many drugs being recalled from the market. But they state that it was fixed over several inspections conducted later. MCC also stated that after FDA banned products from the Paonta Sahib plant of Ranbaxy in 2006, random tests of Ranbaxy drugs on the South African market found no critical deficiencies.</p><p align="justify">According to the WHO, after USFDA issued a warning to Ranbaxy in 2008, WHO-PQP organized several inspection since the Paonta Sahib site also manufactured drugs on WHO's prequalified list. One of these inspections was conducted in November 2008 by a team of 6 inspectors - 3 from WHOPQP, one from the Therapeutic Goods Administration (TGA) of Australia, one from Health Canada and one from MHRA, UK. Some non-compliances were observed and Ranbaxy thereafter submitted documentation describing corrective and preventive actions, which were assessed by the inspection team and found acceptable. &quot;There was no evidence to warrant any further action by WHO-PQP, or indeed by those SRAs who participated in this inspection,&quot; said WHO adding that WHO-PQP has continued to monitor Ranbaxy and all other manufacturers on the WHO list.</p><p align="justify">WHO concluded by giving a list of all the inspections it has conducted along with regulatory authorities from various countries- Swtizerland, France, Hungary, Australia, Kenya, Tanzania South Africa and the UK --since 2000 in Ranbaxy manufacturing sites in Dewas, Mohali and Paonta Sahib.</p><p align="justify">&nbsp;</p>',
	'lang' => 'English',
	'SITE_URL' => 'https://im4change.in/',
	'site_title' => 'im4change',
	'adminprix' => 'admin'
]
$article_current = object(App\Model\Entity\Article) {

	'id' => (int) 21571,
	'title' => 'Ranbaxy drugs fine, say WHO and UK regulator -Rema Nagarajan',
	'subheading' => '',
	'description' => '<div align="justify">
-The Times of India
</div>
<p align="justify">
<br />
<em>NEW DELHI: </em>In yet another twist to the Ranbaxy scandal, the drug regulatory authority of the UK government has issued a statement clarifying that they have found no evidence of any Ranbaxy product in the UK market having been &quot;of unacceptable quality&quot;. Last month, WHO had issued a similar statement. It had said that there was no evidence of any of the Ranbaxy products being of unacceptable quality.
</p>
<p align="justify">
The Medicines and Healthcare products Regulatory Authority (MHRA) of UK explained that on hearing that Ranbaxy had pleaded guilty to felony charges related to drugs made at two facilities in India it had performed a number of inspections of Ranbaxy sites along with other international regulators including the USFDA and the WHO.
</p>
<p align="justify">
While some failures to comply with good manufacturing practice (GMP) were reported, the inspections did not find any Ranbaxy products in the UK market being either of unacceptable quality or putting UK patients at risk. The statement clarified: &quot;As part of their investigations the MHRA has tested samples of Ranbaxy products taken from the UK market. All samples met the correct quality specifications.&quot;
</p>
<p align="justify">
MHRA explained how it has been inspecting Ranbaxy sites since 1995 for GMP compliance and elaborated how following USFDA concerns in 2008, MHRA was part of multinational inspection teams which found that while the company complied in general with European Union (EU) GMP they needed to demonstrate continued commitment to improving standards of compliance. Continuing inspections by international teams showed that &quot;the company had made significant progress&quot;.
</p>
<p align="justify">
According to the MHRA, India is the biggest supplier of Active Pharmaceutical Ingredients (APIs) to the EU and in the last financial year, of the 116 overseas inspections conducted by MHRA, 47 were performed in India and 52 were performed in the US. &quot;There is not a noticeable difference in the number of significant findings identified at UK sites versus those overseas,&quot; added the MHRA. In the UK 23% of UK Marketing Authorisations name an Indian manufacturer and 38% name an Indian API source.
</p>
<p align="justify">
WHO in its statement explained that it has a number of finished pharmaceutical products (FPPs), mostly HIV/AIDS drugs, manufactured by Ranbaxy on its pre-qualified list and added that a number of generic medicines prequalified by the WHO Pre-Qualification Programme (WHO-PQP), including those of Ranbaxy, have also been approved by stringent regulatory authorities (SRAs). SRAs are those national medicines regulatory authorities which are members, observers or associates of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use.
</p>
<p align="justify">
The WHO-PQP statement explained: &quot;In the USA, the term &quot;adulterated&quot; has a specific legal meaning. If a company is not complying with Current Good Manufacturing Practice Regulations (cGMP), any medicines that it manufactures are considered to be &quot;adulterated&quot; under the law. In other words, its medicines are not manufactured under conditions that comply with cGMP. It does not mean that the medicine is necessarily substandard.&quot;
</p>
<p align="justify">
Medicines Control Council (MCC) of South Africa too has assured that Ranbaxy drugs were safe and effective. MCC was part of several inspections conducted of Ranbaxy's manufacturing sites. However, the WHO as well as the MCC said that, in 2004, there were problems with Ranbaxy such as with missing data, changes to dates in documentation, and comparative data not being credible which led to many drugs being recalled from the market. But they state that it was fixed over several inspections conducted later. MCC also stated that after FDA banned products from the Paonta Sahib plant of Ranbaxy in 2006, random tests of Ranbaxy drugs on the South African market found no critical deficiencies.
</p>
<p align="justify">
According to the WHO, after USFDA issued a warning to Ranbaxy in 2008, WHO-PQP organized several inspection since the Paonta Sahib site also manufactured drugs on WHO's prequalified list. One of these inspections was conducted in November 2008 by a team of 6 inspectors - 3 from WHOPQP, one from the Therapeutic Goods Administration (TGA) of Australia, one from Health Canada and one from MHRA, UK. Some non-compliances were observed and Ranbaxy thereafter submitted documentation describing corrective and preventive actions, which were assessed by the inspection team and found acceptable. &quot;There was no evidence to warrant any further action by WHO-PQP, or indeed by those SRAs who participated in this inspection,&quot; said WHO adding that WHO-PQP has continued to monitor Ranbaxy and all other manufacturers on the WHO list.
</p>
<p align="justify">
WHO concluded by giving a list of all the inspections it has conducted along with regulatory authorities from various countries- Swtizerland, France, Hungary, Australia, Kenya, Tanzania South Africa and the UK --since 2000 in Ranbaxy manufacturing sites in Dewas, Mohali and Paonta Sahib.
</p>
<p align="justify">
&nbsp;
</p>',
	'credit_writer' => 'The Times of India, 28 June, 2013, http://timesofindia.indiatimes.com/business/india-business/Ranbaxy-drugs-fine-say-WHO-and-UK-regulator/articleshow/20806204.cms',
	'article_img' => '',
	'article_img_thumb' => '',
	'status' => (int) 1,
	'show_on_home' => (int) 1,
	'lang' => 'EN',
	'category_id' => (int) 16,
	'tag_keyword' => '',
	'seo_url' => 'ranbaxy-drugs-fine-say-who-and-uk-regulator-rema-nagarajan-21718',
	'meta_title' => null,
	'meta_keywords' => null,
	'meta_description' => null,
	'noindex' => (int) 0,
	'publish_date' => object(Cake\I18n\FrozenDate) {},
	'most_visit_section_id' => null,
	'article_big_img' => null,
	'liveid' => (int) 21718,
	'created' => object(Cake\I18n\FrozenTime) {},
	'modified' => object(Cake\I18n\FrozenTime) {},
	'edate' => '',
	'tags' => [
		(int) 0 => object(Cake\ORM\Entity) {},
		(int) 1 => object(Cake\ORM\Entity) {},
		(int) 2 => object(Cake\ORM\Entity) {}
	],
	'category' => object(App\Model\Entity\Category) {},
	'[new]' => false,
	'[accessible]' => [
		'*' => true,
		'id' => false
	],
	'[dirty]' => [],
	'[original]' => [],
	'[virtual]' => [],
	'[hasErrors]' => false,
	'[errors]' => [],
	'[invalid]' => [],
	'[repository]' => 'Articles'

}
$articleid = (int) 21571
$metaTitle = 'LATEST NEWS UPDATES | Ranbaxy drugs fine, say WHO and UK regulator -Rema Nagarajan'
$metaKeywords = 'medicines,Ranbaxy,Health'
$metaDesc = '
-The Times of India



NEW DELHI: In yet another twist to the Ranbaxy scandal, the drug regulatory authority of the UK government has issued a statement clarifying that they have found no evidence of any Ranbaxy product in the UK market...'
$disp = '<div align="justify">-The Times of India</div><p align="justify"><br /><em>NEW DELHI: </em>In yet another twist to the Ranbaxy scandal, the drug regulatory authority of the UK government has issued a statement clarifying that they have found no evidence of any Ranbaxy product in the UK market having been &quot;of unacceptable quality&quot;. Last month, WHO had issued a similar statement. It had said that there was no evidence of any of the Ranbaxy products being of unacceptable quality.</p><p align="justify">The Medicines and Healthcare products Regulatory Authority (MHRA) of UK explained that on hearing that Ranbaxy had pleaded guilty to felony charges related to drugs made at two facilities in India it had performed a number of inspections of Ranbaxy sites along with other international regulators including the USFDA and the WHO.</p><p align="justify">While some failures to comply with good manufacturing practice (GMP) were reported, the inspections did not find any Ranbaxy products in the UK market being either of unacceptable quality or putting UK patients at risk. The statement clarified: &quot;As part of their investigations the MHRA has tested samples of Ranbaxy products taken from the UK market. All samples met the correct quality specifications.&quot;</p><p align="justify">MHRA explained how it has been inspecting Ranbaxy sites since 1995 for GMP compliance and elaborated how following USFDA concerns in 2008, MHRA was part of multinational inspection teams which found that while the company complied in general with European Union (EU) GMP they needed to demonstrate continued commitment to improving standards of compliance. Continuing inspections by international teams showed that &quot;the company had made significant progress&quot;.</p><p align="justify">According to the MHRA, India is the biggest supplier of Active Pharmaceutical Ingredients (APIs) to the EU and in the last financial year, of the 116 overseas inspections conducted by MHRA, 47 were performed in India and 52 were performed in the US. &quot;There is not a noticeable difference in the number of significant findings identified at UK sites versus those overseas,&quot; added the MHRA. In the UK 23% of UK Marketing Authorisations name an Indian manufacturer and 38% name an Indian API source.</p><p align="justify">WHO in its statement explained that it has a number of finished pharmaceutical products (FPPs), mostly HIV/AIDS drugs, manufactured by Ranbaxy on its pre-qualified list and added that a number of generic medicines prequalified by the WHO Pre-Qualification Programme (WHO-PQP), including those of Ranbaxy, have also been approved by stringent regulatory authorities (SRAs). SRAs are those national medicines regulatory authorities which are members, observers or associates of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use.</p><p align="justify">The WHO-PQP statement explained: &quot;In the USA, the term &quot;adulterated&quot; has a specific legal meaning. If a company is not complying with Current Good Manufacturing Practice Regulations (cGMP), any medicines that it manufactures are considered to be &quot;adulterated&quot; under the law. In other words, its medicines are not manufactured under conditions that comply with cGMP. It does not mean that the medicine is necessarily substandard.&quot;</p><p align="justify">Medicines Control Council (MCC) of South Africa too has assured that Ranbaxy drugs were safe and effective. MCC was part of several inspections conducted of Ranbaxy's manufacturing sites. However, the WHO as well as the MCC said that, in 2004, there were problems with Ranbaxy such as with missing data, changes to dates in documentation, and comparative data not being credible which led to many drugs being recalled from the market. But they state that it was fixed over several inspections conducted later. MCC also stated that after FDA banned products from the Paonta Sahib plant of Ranbaxy in 2006, random tests of Ranbaxy drugs on the South African market found no critical deficiencies.</p><p align="justify">According to the WHO, after USFDA issued a warning to Ranbaxy in 2008, WHO-PQP organized several inspection since the Paonta Sahib site also manufactured drugs on WHO's prequalified list. One of these inspections was conducted in November 2008 by a team of 6 inspectors - 3 from WHOPQP, one from the Therapeutic Goods Administration (TGA) of Australia, one from Health Canada and one from MHRA, UK. Some non-compliances were observed and Ranbaxy thereafter submitted documentation describing corrective and preventive actions, which were assessed by the inspection team and found acceptable. &quot;There was no evidence to warrant any further action by WHO-PQP, or indeed by those SRAs who participated in this inspection,&quot; said WHO adding that WHO-PQP has continued to monitor Ranbaxy and all other manufacturers on the WHO list.</p><p align="justify">WHO concluded by giving a list of all the inspections it has conducted along with regulatory authorities from various countries- Swtizerland, France, Hungary, Australia, Kenya, Tanzania South Africa and the UK --since 2000 in Ranbaxy manufacturing sites in Dewas, Mohali and Paonta Sahib.</p><p align="justify">&nbsp;</p>'
$lang = 'English'
$SITE_URL = 'https://im4change.in/'
$site_title = 'im4change'
$adminprix = 'admin'

include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51

Ranbaxy drugs fine, say WHO and UK regulator -Rema Nagarajan

-The Times of India NEW DELHI: In yet another twist to the Ranbaxy scandal, the drug regulatory authority of the UK government has issued a statement clarifying that they have found no evidence of any Ranbaxy product in the UK market having been "of unacceptable quality". Last month, WHO had issued a similar statement. It had said that there was no evidence of any of the Ranbaxy products being of unacceptable quality. The Medicines and Healthcare products Regulatory Authority (MHRA) of UK explained that on hearing that Ranbaxy had pleaded guilty to felony charges related to drugs made at two facilities in India it had performed a number of inspections of Ranbaxy sites along with other international regulators including the USFDA and the WHO. While some failures to comply with good manufacturing practice (GMP) were reported, the inspections did not find any Ranbaxy products in the UK market being either of unacceptable quality or putting UK patients at risk. The statement clarified: "As part of their investigations the MHRA has tested samples of Ranbaxy products taken from the UK market. All samples met the correct quality specifications." MHRA explained how it has been inspecting Ranbaxy sites since 1995 for GMP compliance and elaborated how following USFDA concerns in 2008, MHRA was part of multinational inspection teams which found that while the company complied in general with European Union (EU) GMP they needed to demonstrate continued commitment to improving standards of compliance. Continuing inspections by international teams showed that "the company had made significant progress". According to the MHRA, India is the biggest supplier of Active Pharmaceutical Ingredients (APIs) to the EU and in the last financial year, of the 116 overseas inspections conducted by MHRA, 47 were performed in India and 52 were performed in the US. "There is not a noticeable difference in the number of significant findings identified at UK sites versus those overseas," added the MHRA. In the UK 23% of UK Marketing Authorisations name an Indian manufacturer and 38% name an Indian API source. WHO in its statement explained that it has a number of finished pharmaceutical products (FPPs), mostly HIV/AIDS drugs, manufactured by Ranbaxy on its pre-qualified list and added that a number of generic medicines prequalified by the WHO Pre-Qualification Programme (WHO-PQP), including those of Ranbaxy, have also been approved by stringent regulatory authorities (SRAs). SRAs are those national medicines regulatory authorities which are members, observers or associates of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. The WHO-PQP statement explained: "In the USA, the term "adulterated" has a specific legal meaning. If a company is not complying with Current Good Manufacturing Practice Regulations (cGMP), any medicines that it manufactures are considered to be "adulterated" under the law. In other words, its medicines are not manufactured under conditions that comply with cGMP. It does not mean that the medicine is necessarily substandard." Medicines Control Council (MCC) of South Africa too has assured that Ranbaxy drugs were safe and effective. MCC was part of several inspections conducted of Ranbaxy's manufacturing sites. However, the WHO as well as the MCC said that, in 2004, there were problems with Ranbaxy such as with missing data, changes to dates in documentation, and comparative data not being credible which led to many drugs being recalled from the market. But they state that it was fixed over several inspections conducted later. MCC also stated that after FDA banned products from the Paonta Sahib plant of Ranbaxy in 2006, random tests of Ranbaxy drugs on the South African market found no critical deficiencies. According to the WHO, after USFDA issued a warning to Ranbaxy in 2008, WHO-PQP organized several inspection since the Paonta Sahib site also manufactured drugs on WHO's prequalified list. One of these inspections was conducted in November 2008 by a team of 6 inspectors - 3 from WHOPQP, one from the Therapeutic Goods Administration (TGA) of Australia, one from Health Canada and one from MHRA, UK. Some non-compliances were observed and Ranbaxy thereafter submitted documentation describing corrective and preventive actions, which were assessed by the inspection team and found acceptable. "There was no evidence to warrant any further action by WHO-PQP, or indeed by those SRAs who participated in this inspection," said WHO adding that WHO-PQP has continued to monitor Ranbaxy and all other manufacturers on the WHO list. WHO concluded by giving a list of all the inspections it has conducted along with regulatory authorities from various countries- Swtizerland, France, Hungary, Australia, Kenya, Tanzania South Africa and the UK --since 2000 in Ranbaxy manufacturing sites in Dewas, Mohali and Paonta Sahib.